Insulet’s Omnipod DASH Insulin Management System Receives FDA 510(k) Clearance

Medical Device Investing

Insulet (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced FDA 510(k) clearance of the Omnipod DASHTM Insulin Management System (Omnipod DASH). As quoted in the press release: “Omnipod DASH was inspired by Podders and embodies what users on multiple daily injections have been asking for in …

Insulet (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod^® Insulin Management System (Omnipod System), today announced FDA 510(k) clearance of the Omnipod DASH^TM Insulin Management System (Omnipod DASH).

As quoted in the press release:

“Omnipod DASH was inspired by Podders and embodies what users on multiple daily injections have been asking for in a diabetes management system,” said Patrick Sullivan, Chairman and Chief Executive Officer. “Our number one priority is to continue to minimize the daily strain on those impacted by diabetes and we are confident this system, and eliminating the system’s upfront cost, do just that.”
Omnipod DASH was built to be simple, discreet and easy-to-use. The system features Bluetooth wireless technology for connectivity between the color touch-screen Personal Diabetes Manager (PDM), tubeless waterproof pump (Pod), and is optimized for use with the CONTOUR^® NEXT ONE Blood Glucose (BG) Meter for the seamless transfer of blood glucose readings to the PDM’s bolus calculator. Bluetooth functionality also provides connectivity to the Omnipod DISPLAY^™ and Omnipod VIEW^™ apps. The DASH PDM will be offered at no cost with the purchase of Pods.

Click here to read the full press release.

Medical Device Investing